Health Economics›Diffuse large B-cell lymphoma›Relapsed or refractory further lines of therapy

Relapsed or refractory further lines of therapy

Diffuse large B-cell lymphoma · 48 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bendamustine and Rituximab (BR) and Polatuzumab vedotin Variant #01	—	R 264 184	21d	—	12.4 mo	—	—	1
ViPOR Variant #01	—	R 237 624	21d	—	—	—	—	—
Glofitamab monotherapy Variant #01	—	R 219 579	21d	—	—	—	—	—
Obinutuzumab monotherapy Variant #03	—	R 166 941	21d	—	—	—	—	—
Everolimus and Rituximab Variant #01	—	R 91 109	28d	—	—	—	—	—
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	—	8.5 mo	—	—	1
Brentuximab vedotin monotherapy Variant #01	—	R 85 244	21d	~25.6 mo	—	~38	~R 3 239 268 PFS proxy · indirect	2
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~22.1 mo	~30.3 mo	~25	~R 2 003 321 PFS proxy · indirect	2
Gemcitabine and Rituximab Variant #02	—	R 63 243	28d	—	9.5 mo	—	—	1
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	—	9.5 mo	—	—	1
R-BL Variant #02	—	R 29 259	28d	—	—	—	—	—
Ibritumomab tiuxetan protocol Variant #18	—	R 27 524	8d	~36.5 mo	—	~139	~R 3 825 804 PFS proxy · indirect	1
TTR Variant #01	—	R 20 892	21d	—	—	—	—	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~7	~R 128 518 PFS proxy · indirect	15
R-GemOx Variant #04	—	R 16 789	21d	3.8 mo	12.9 mo	6	R 100 734 PFS proxy	2
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~5.2 mo	—	~3	~R 42 639 PFS proxy · indirect	1
GVD Variant #01	—	R 13 431	21d	—	—	—	—	—
R-CVEP Variant #01 Partial	—	R 12 366	28d	—	—	—	—	—
R-INO Variant #01 Partial	—	R 11 796	28d	—	9.5 mo	—	—	1
Panobinostat and Rituximab Variant #01 Partial	—	R 11 796	21d	—	—	—	—	—
ICE Variant #01	—	R 11 539	14d	—	~13.9 mo	—	—	—
Etoposide, Ifosfamide, Methotrexate Variant #01	—	R 10 515	21d	—	—	—	—	—
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	~4.0 mo	~8.4 mo	~5	~R 49 173 PFS proxy · indirect	2
DICE Variant #01	—	R 9 816	28d	—	—	—	—	—
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	—	—	—	—	1
Lenalidomide and Tafasitamab Variant #01 Partial	—	R 5 445	28d	—	—	—	—	—
DICEP Variant #01	—	R 5 437	—	—	—	—	—	—
Bendamustine monotherapy Variant #01	—	R 5 419	—	~16.5 mo	—	—	—	2
Mitoxantrone monotherapy Variant #01	—	R 4 881	21d	—	—	—	—	—
ESHAP Variant #01	—	R 3 716	21d	—	—	—	—	—
GDP Variant #01	—	R 3 565	21d	—	—	—	—	—
Etoposide monotherapy Variant #01	—	R 2 872	28d	—	—	—	—	—
EPOCH Variant #01	—	R 1 505	21d	—	—	—	—	—
Oxaliplatin monotherapy Variant #01	—	R 1 075	21d	—	—	—	—	—
CEPP(B) Variant #01 Partial	—	R 1 058	30d	—	—	—	—	—
Vinorelbine monotherapy Variant #01	—	R 583	21d	~4.0 mo	~9.4 mo	~6	~R 3 500 PFS proxy · indirect	26
Epcoritamab monotherapy N/A - secondary systemic drug	—	R 169	—	—	—	—	—	—
Loncastuximab tesirine monotherapy N/A - secondary systemic drug	—	R 139	21d	—	—	—	—	—
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~5.2 mo	—	~1	~R 52 PFS proxy · indirect	3
Blinatumomab monotherapy N/A - secondary systemic drug	—	R 18	28d	—	~7.7 mo	—	—	2
Ofatumumab monotherapy N/A - secondary systemic drug	—	R 2	56d	~8.1 mo	—	~5	~R 9 PFS proxy · indirect	4
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	~4.8 mo	~23.5 mo	~6	~R 1 PFS proxy · indirect	2
Axicabtagene ciloleucel monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	1
Selinexor monotherapy Variant #01 Partial	—	—	7d	~2.8 mo	—	~13	—	1
Pixantrone monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Panobinostat monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—

48 of 48 regimens shown